FIT Biotech Oy
Company release December 19, 2017 at 3 pm EET DRAFT
FIT Biotech Ltd’s own equity negative in the end of November
The Company’s own equity including additions according to the Companies Act as of 30.11.2017 was 109,600 euro negative. The Board of Directors has taken immediate actions to turn the equity positive.
The Board of Directors is actively following the financial situation of the Company and will disclose further information as soon as possible.
FIT BIOTECH OY
Board of Directors
For further information:
Chairman of the Board of Directors Rabbe Slätis
Tel: +358 40 840 6749
E-mail: rabbe.slatis@fitbiotech.com
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
